Increase of C-type natriuretic peptide expression by serum and platelet-derived growth factor-BB in human aortic smooth muscle cells is dependent on protein kinase C activation.
C-type natriuretic peptide (CNP) is produced by the vascular smooth muscle cells (SMCs) of injured and atherosclerotic arteries, in which it may exert autocrine control over SMCs by binding to its principal receptors, NPR-B and NPR-C, but few studies have examined the factors that regulate CNP expression in human SMCs. In the present report, we show that serum induces significant increases in both CNP and NPR-C transcript levels in human, but not rat SMCs in culture, and that pretreatment with either the general tyrosine kinase inhibitor genistein, the platelet-derived growth factor (PDGF) tyrosine kinase inhibitor AG 1296, or the protein kinase C (PKC) inhibitor GF109203X blocks most of the serum-induced increase in CNP. PDGF-BB also induced significant dose-dependent increases in CNP transcript that correlated temporally with the serum effect on CNP mRNA. Inhibition of several PDGF-BB signaling pathways downstream of receptor activation showed that PKC inhibition with GF109203X was almost as effective as genistein in abolishing the PDGF-BB-induced up-regulation of CNP mRNA. Furthermore, PKC activation by phorbol 12-myristate 13-acetate (PMA) produced an extremely high level of CNP mRNA that was abolished by GF109203X. Immunoreactive CNP was markedly increased in SMCs receiving 10% serum, 20 ng/ml PDGF-BB, or PMA, and was decreased in PDGF-treated and PMA-treated cells by AG 1296 and GF109203X, respectively. This report suggests that in humans, PDGF and other factors signaling through receptor tyrosine kinases and downstream activation of PKC could represent an important control for CNP expression in vascular smooth muscle.
Mendonça
Maria C
MC
Department of Medicine, Division of Endocrinology and Nephrology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, A3060, Bethesda, Maryland 20814-4799, USA.
Doi
Sonia Q
SQ
Glerum
Steven
S
Sellitti
Donald F
DF
D000818:Animals; D001011:Aorta; D000077214:Becaplermin; D001769:Blood; D002478:Cells, Cultured; D003470:Culture Media; D042783:Endothelial Cells / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D015870:Gene Expression; D019833:Genistein / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008301:Maleimides / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D020098:Natriuretic Peptide, C-Type / Q000235:genetics*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics; D013045:Species Specificity; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D020032:Tyrphostins / Q000494:pharmacology
D003470:Culture Media; D007211:Indoles; D008301:Maleimides; D010982:Platelet-Derived Growth Factor; D047428:Protein Kinase Inhibitors; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D020032:Tyrphostins; D020098:Natriuretic Peptide, C-Type; C106250:6,7-dimethoxy-3-phenylquinoxaline; D000077214:Becaplermin; D019833:Genistein; D011493:Protein Kinase C; D017461:Receptors, Atrial Natriuretic Factor; C073616:atrial natriuretic factor receptor C; C070515:bisindolylmaleimide I; D013755:Tetradecanoylphorbol Acetate